Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the company from $35 to $40, signaling increased confidence in the stock's potential.

The upgrade from Leerink Partners suggests that analysts see improved prospects for Castle Biosciences, a company known for its innovative diagnostic and prognostic tests for dermatological cancers. This vote of confidence from a respected financial firm appears to be driving investor enthusiasm, resulting in the significant pre-market price increase.

While specific reasons for the target price increase were not provided in the available information, such upgrades are typically based on factors like improved financial performance, promising product developments, or positive industry trends. Investors are advised to monitor any forthcoming detailed reports from Leerink Partners for a more comprehensive understanding of the factors behind this bullish outlook.